Nate Pile started in the Electrical Engineering/Computer Science program at U.C. Berkeley, but wound up with a degree in Mathematics from Cal. While in school, he was lucky enough to meet and spend time working for legendary biotech analyst Jim McCamant, a life-changing experience that inspired Pile to eventually launch his own newsletter, Nate’s Notes, in 1995.
Articles by Nate Pile
More than 214,000 shares have been purchased by the insiders of this biotech in the past three months. The shares are trading a very price, reflecting the company’s turnaround status.
This fund is an opportunity to diversify your biotech holdings. It has a current dividend yield of 8.87%, paid quarterly.
This healthcare fund just paid a distribution of $0.36 per share on March 31. The previous payment was in November, 2016, for $.040.
TheStreet.com also likes this biotech, recently noting, “A clear take out of the February highs, just above $117.65, could provide the spark needed to send the biotech stock sharply higher.”
From Nate’s Notes
Despite providing some very encouraging guidance at the JP Morgan Conference this...
This previous Top Pick is trying to overcome a dismal 2016. The company received a $1 million milestone payment from Receptor Life Sciences, Inc. (RLS) at the end of the year, and analysts are forecasting 80%+ growth in 2017 for the company. However, aware...
This tech company posted EPS of $0.44 last quarter, handily beating analysts’ estimates of $0.28 per share. Nine analysts have raised their forecasts for the company in the past 30 days.
Cirrus Logic (CRUS)From Nate’s Notes
Cirrus Logic (CRUS) has also joined the parade of that...
The top four regions that this fund is invested in are: North America (94.60%); Greater Europe (5.40%); Europe Developed (1.35%); and Africa/Middle East (4.05%). The fund has a current dividend yield of 9.33%, paid quarterly.
Tekla Life Sciences Investors (HQL)
From Nate’s Notes
My Top Income for...
This graphics chip maker is seeing some interesting option activity, with buyers loading up on calls in the past month. The shares have responded accordingly, but remain a buy.
NVIDIA (NVDA) from Nate’s Notes
NVIDIA (NVDA) is currently demonstrating some of the best relative strength all...
Nate’s Notes is a monthly newsletter focused on helping individual investors grow their net worth over time via a disciplined, long-term approach to investing in the stock market. Emphasis is placed on finding companies with “best of class” products and management teams, then...